389 related articles for article (PubMed ID: 27264969)
21. Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Shukla N; Somwar R; Smith RS; Ambati S; Munoz S; Merchant M; D'Arcy P; Wang X; Kobos R; Antczak C; Bhinder B; Shum D; Radu C; Yang G; Taylor BS; Ng CK; Weigelt B; Khodos I; de Stanchina E; Reis-Filho JS; Ouerfelli O; Linder S; Djaballah H; Ladanyi M
Cancer Res; 2016 Aug; 76(15):4525-34. PubMed ID: 27256563
[TBL] [Abstract][Full Text] [Related]
22. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
Liu N; Li X; Huang H; Zhao C; Liao S; Yang C; Liu S; Song W; Lu X; Lan X; Chen X; Yi S; Xu L; Jiang L; Zhao C; Dong X; Zhou P; Li S; Wang S; Shi X; Dou PQ; Wang X; Liu J
Oncotarget; 2014 Jul; 5(14):5453-71. PubMed ID: 24977961
[TBL] [Abstract][Full Text] [Related]
23. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
26. Dienone Compounds: Targets and Pharmacological Responses.
Bazzaro M; Linder S
J Med Chem; 2020 Dec; 63(24):15075-15093. PubMed ID: 33146523
[TBL] [Abstract][Full Text] [Related]
27. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Colland F
IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
[No Abstract] [Full Text] [Related]
29. Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction.
Vaden JH; Bhattacharyya BJ; Chen PC; Watson JA; Marshall AG; Phillips SE; Wilson JA; King GD; Miller RJ; Wilson SM
Mol Neurodegener; 2015 Jan; 10():3. PubMed ID: 25575639
[TBL] [Abstract][Full Text] [Related]
30. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J
Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524
[TBL] [Abstract][Full Text] [Related]
31. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
[TBL] [Abstract][Full Text] [Related]
32. Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.
Chadchankar J; Korboukh V; Conway LC; Wobst HJ; Walker CA; Doig P; Jacobsen SJ; Brandon NJ; Moss SJ; Wang Q
PLoS One; 2019; 14(11):e0225145. PubMed ID: 31703099
[TBL] [Abstract][Full Text] [Related]
33. Proteasome-associated cysteine deubiquitinases are molecular targets of environmental optical brightener compounds.
Castro I; Ekinci E; Huang X; Cheaito HA; Ahn YH; Olivero-Verbel J; Dou QP
J Cell Biochem; 2019 Aug; 120(8):14065-14075. PubMed ID: 30963630
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
36. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system.
Selvaraju K; Mofers A; Pellegrini P; Salomonsson J; Ahlner A; Morad V; Hillert EK; Espinosa B; Arnér ESJ; Jensen L; Malmström J; Turkina MV; D'Arcy P; Walters MA; Sunnerhagen M; Linder S
Sci Rep; 2019 Jul; 9(1):9841. PubMed ID: 31285509
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
39. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
40. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
